Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1986-07-23
1990-07-03
Martinell, James
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
4351722, 43524026, 43524027, 435 7021, 424 858, 436548, 935104, C12P 2100, C12N 1500, C12N 500, A61K 39395, C07K 1500, G01N 3353
Patent
active
RE0332526
ABSTRACT:
A process for producing anti-IL-2 antibody from hybridoma cells generated by fusing activated, IL-2 immunized, murine lymphocyte cells with neoplastic murine myeloma cells. Fusion is accomplished by mixing the two cell lines together in the presence of a fusing agent. After fusion, the hybridoma cells are cultured in vitro in a supplemented tissue culture medium to thereby produce anti-IL-2 antibody. Also, the hybridoma cells are cloned by a limiting dilution procedure to isolate even more potent sources of anti-IL-2 antibody. Anti-IL-2 antibody is then purified from either tissue culture medium conditioned by hybridoma cells, or from peritoneal ascites of mice challenged with hybridoma cells.
REFERENCES:
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4411993 (1983-10-01), Gillis
Stadler et al; "Charge Heterogeneity of Human Interleukin 2 (IL 2) and Inhibition of IL 2 Activity by Supernatant of Hybridomas Generated from Spleen Cells Immunized with IL 2", Fed. Proc. 40 (3 part II), 1111, Abstr. No. 5002 (1981).
Luben et al; "Production of Hybridomas Secreting Monoclonal Antibodies Against the Lymphokine Osteoclast Activating Factor", 154 Journal of Clinical Investigation, 1262, 64: 337 (1979).
Luben et al., "Use of in vitro Immunization in Production of Monoclonal Antibodies Against Osteoclast-Activating Factor: A Method with General Applicability to Lymphokines" in Biochemical Characterization of Lymphokines, 1979, DeWeck et al (ed.), Academic Press, New York, beginning at p. 321.
Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", Nature 256:497 (1975).
Gillis, et al., "Long Term Culture of Tumour-Specific Cytotoxic T Cells", Nature 268:154 (1977).
Gillis, et al., "T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity", J. Immunol. 120:2027 (1978).
Watson, et al., "Biochemical and Biological Characterization of Lymphocyte Regulatory Molecules-I. Purification of a Class of Murine Lymphokines", J. Exp. Med. 150:849 (1979).
Gillis, et al., "Biochemical Characterization of Lymphocyte Regulatory Molecules-II. Purification of a Class of Rat and Human Lymphokines", J. Immunol. 124:1954 (1980).
Gillis and Watson, "Biochemical and Biological Characterization of Lymphocyte Regulatory Molecules V. Identification of an IL-2 Producing Human Leukemia T Cell Line", J. Exp. Med. 152:1709 (1980).
Gillis and Watson, "Functional Activity and Biochemical Characterization of IL-2 Produced by Murine Tumor Cell Lines", Behring Inst. Mitt. 67:48 (1980).
Immunex Corporation
Martinell James
LandOfFree
Hybridoma antibody which inhibits Interleukin 2 activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybridoma antibody which inhibits Interleukin 2 activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybridoma antibody which inhibits Interleukin 2 activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1881495